Ординатура / Офтальмология / Английские материалы / Shields Textbook of Glaucoma, 6th edition_Allingham, Damji, Freedman_2010

baseline to 21.5 ± 5.9 mm Hg after 3 months of treatment (48). In a study of 36 Japanese patients with chronic angleclosure glaucoma treated by laser iridotomy, the effects of latanoprost alone versus the unfixed combination therapy of timolol maleate, 0.5%, and dorzolamide hydrochloride, 1%, were compared (49). After 12 weeks of treatment, latanoprost reduced the IOP by 33%, from 22.2 ± 2.0 to 14.8 ± 1.9 mm Hg. Timolol maleate and dorzolamide hydrochloride reduced IOP by 24%, from 22.5 ± 2.2 to 17.1 ± 2.7 mm Hg. Finally, in 32 patients who had previous peripheral iridectomy and inadequate IOP, half of the group was randomly assigned to latanoprost and the other half to timolol (50). Latanoprost lowered the IOP by 8.8 mm Hg (34% reduction from a baseline of 25.7 mm Hg), compared with 5.7 mm Hg for timolol (23% reduction from a baseline of 25.2 mm Hg). Thus, when IOP elevation persists after peripheral iridectomy in patients with primary angle-closure glaucoma, latanoprost is effective in lowering the IOP.

Unoprostone

Unlike the 20-carbon molecular skeleton of arachidonic acid, unoprostone, also known as UF-021, may be considered a docosanoid, which is a 22-carbon molecule (Fig. 28.2). Unoprostone has been in clinical use in Japan since 1994 in a 0.12% formulation. Unoprostone, 0.15%, became available for clinical use in the United States in 2000. Studies in Japan have shown that unoprostone, 0.12%, administered two times daily lowered IOP by 11% to 23% from baseline (51, 52 and 53).

Comparison studies between unoprostone and timolol have shown that unoprostone is not as effective as timolol at decreasing the IOP (54, 55). The effectiveness of unoprostone has also been compared with latanoprost. In a comparative parallel-group study in a total of 108 patients, there was a mean IOP reduction of 6.7 mm Hg in the group treated with latanoprost, compared with 3.3 mm Hg lowering in the unoprostone-treated group (56). Similar results showing better efficacy of latanoprost compared with unoprostone were shown in a smaller study of patients with ocular hypertension (57).

A recent study demonstrated that unoprostone increased activity of certain tissue inhibitors of matrix metalloproteinase in cultured human ciliary body smooth muscle cells, compared with bimatoprost and latanoprost (58). It is proposed that this differential effect of the prostaglandin agents may explain the lower clinical efficacy of unoprostone compared with the other agents.

Travoprost

Travoprost, also known as AL-6221, was approved for clinical use in the United States in 2001 (59). The effectiveness of travoprost has been compared with that of timolol and latanoprost.

In a 9-month clinical trial with 573 patients, travoprost showed a 30% to 33% decrease in IOP from baseline compared with a 25% to 29% decrease in IOP in patients using timolol, 0.5%, twice daily (60). In a 6-month comparative study of travoprost and timolol involving 605 patients, the IOP decrease from baseline ranged from -6.5 to -8.0 mm Hg for travoprost, 0.004%, and -5.2 to -7.0 mm Hg for timolol (61). In a 12month comparative clinical trial of travoprost, latanoprost, and timolol involving 801 patients, the IOP-lowering effect of travoprost was greater than the timolol and similar to that of latanoprost (62). In another clinical trial of 426 patients with uncontrolled IOP on timolol alone, travoprost led to further, significant IOP reduction after 6 months of treatment (63).

P.405

Travoprost has also been shown to be effective in lowering IOP in patients with chronic angle-closure glaucoma (46, 64).

Travoprost was observed to be more effective in lowering IOP compared with latanoprost in blacks compared with nonblack patients (62, 65). However, subsequent studies have not reproduced this observation. In a small, randomized, investigator-masked multicenter study, 83 patients with openangle glaucoma were self-identified as white or other (i.e., African, East Indian, Asian, or Hispanic) and were randomly assigned to receive one of three prostaglandin-prostamide drugs (66). After 24 weeks of treatment, there was a significant decrease in IOP compared with baseline. In this study, there were no differences in treatment effect between the three drugs or between the two ethnic groups, and there was no interaction between race and drug. The results from this smaller study confirmed the observation in the larger Ocular Hypertension Treatment Study (67). The IOP response to prostaglandin analogs was

slightly greater in self-declared African American participants compared with whites, but this difference was not statistically significant. The greater IOP reduction was associated with a higher baseline IOP and a thinner central corneal measurement.

Bimatoprost

Bimatoprost, which was also known as AGN 192024, was approved for clinical use in the United States in 2001. Its chemical structure differs from PGF2a and the other prostaglandin analogs (Fig. 28.2) with

an amide ethyl group at the C-1 position. There is growing evidence to support the designation of this agent as a prostamide, given the identification of the cyclooxygenase-2 (COX-2)-derived oxidation products of the endocannabinoids and the recent discovery and development of prostamide antagonists (68, 69 and 70).

Bimatoprost is hydrolyzed by the cornea to a lesser extent than with latanoprost, unoprostone, and travoprost into the active free acid form of the drug (8). The IOP lowering of bimatoprost (30.4% lowering with once-daily dosing) is greater than that of timolol (26.2% lowering with twice-daily dosing) (71). Similar treatment results have been shown in other clinical studies comparing bimatoprost and timolol (72, 73). Bimatoprost has been compared with latanoprost and showed a similar IOPlowering effect (74, 75 and 76). In a community-based “switch study” involving 1283 patients who were changed from latanoprost to bimatoprost treatment, there was a mean IOP reduction of 3.4 mm Hg after 2 months of bimatoprost treatment (77). In such a “ switch” study, however, the observed IOP reduction may simply reflect a regression to the mean with repeated IOP measurements over time (78). Bimatoprost has also been shown to lower IOP in patients with chronic angle-closure glaucoma. In a meta-analysis of nine randomized clinical trials enrolling a total of 1090 patients, bimatoprost lowered the diurnal IOP curve by 26%, the peak IOP by 28%, and the trough IOP by 27% (46). Timolol lowered the diurnal IOP curve by 23%, the peak IOP by 24%, and the trough IOP by 21%. Other studies also showed that bimatoprost was effective compared with latanoprost in lowering IOP in chronic angleclosure glaucoma (79, 80).

There is some evidence to support that bimatoprost has both FP-receptor agonist activity and possibly another mechanism of action related to trabecular outflow and an alternative signaling pathway based on an assay in feline iris (70, 81, 82).

ADMINISTRATION

Latanoprost, 0.005%, travoprost, 0.004%, and bimatoprost, 0.03%, are administered similarly as one drop daily to the eye. More frequent dosing of these particular agents resulted in reduced efficacy of the drug (71, 83). In contrast, unoprostone, 0.15%, is administered as one drop two times daily to the eye. The dosing regimen for this drug class is unusual given that the pharmacokinetic data indicate a very

short plasma elimination half-life (t1/2 life of 9.2 minutes after intravenous administration and 2.3

minutes after topical administration for latanoprost; t1/2 life of 45 minutes after intravenous administration for bimatoprost) (84, 85 and 86). This molecule is dosed at what appears to be homeopathic levels, but at this dose, it has profound clinical effects on IOP reduction in most patients. The explanation for this dosing regimen and the efficacy is not fully understood on the basis of our present knowledge of the pharmacology and mechanism of action of this drug class (as discussed in the earlier section).

The issue of the effect of storage temperature has been raised with these agents because one study reported that latanoprost exhibits thermal and ultraviolet instability (87). This raises issues related to chemical stability of the molecule and to the role of the composition of the dispensing system on bioavailability of the drug. A comparative study with the other agents in this drug class has not been reported. It has been suggested that unopened bottles of latanoprost be stored under refrigeration. Once opened, latanoprost may be stored at room temperature (as high as 25°C, or 77°F) for up to 6 weeks. The other agents are recommended to be stored at room temperature (15°C to 25°C, or 59°F to 77°F, for bimatoprost; 2°C to 25°C, or 36°F to 77°F, for trav oprost and unoprostone).

DRUG INTERACTION

Given the additional 13% to 37% IOP lowering by combining a uveoscleral outflow drug together with

the aqueous humor inflow suppressant timolol (88, 89), fixed combinations of the prostaglandin agents with timolol have been studied. In other countries, the fixed combination of latanoprost, 0.005%, and timolol, 0.5%, was approved for clinical use in Europe during the summer of 2001 and has been shown to be effective and comparable with each component given separately (90, 91 and 92). The fixed combination of travoprost, 0.004%, and timolol, 0.5%, and bimatoprost and timolol, 0.5%, are also available in other countries (93, 94, 95, 96 and 97). At present, none of these agents are approved for use in the United States.

P.406

The combination of the prostaglandin agents in addition to oral and topical carbonic anhydrase inhibitors (CAIs) have been examined. In 24 patients with glaucoma, a mean IOP of 19.5 mm Hg was achieved while on treatment with acetazolamide (250 mg twice daily), which decreased to 16.8 mm Hg, which was a 15% IOP reduction, after 15 days of combination treatment with latanoprost (0.005% once daily) and acetazolamide (250 mg twice daily) (98). Topical CAIs were also shown to have additional IOPlowering effect in combination with latanoprost (99). A similar effect was observed with travoprost (100, 101).

The combination of the prostaglandin agent bimatoprost and the a2-adrenergic agonist brimonidine has

been compared with the combination of timolol and latanoprost in 28 patients (102). The mean IOP at baseline was 24.8 mm Hg. There was a decrease of 8.5 to 9.0 mm Hg after treatment with bimatoprost combined with brimonidine, and 7.5 to 7.7 mm Hg after treatment with latanoprost combined with timolol. Another study compared combination therapy of brimonidine and latanoprost to the fixed combination of timolol and dorzolamide in patients with glaucoma or ocular hypertension (103). The brimonidine and latanoprost combination was associated with a mean IOP reduction of 9.2 mm Hg. This IOP decrease with use of the combination of the prostaglandin-related drugs and brimonidine is greater than the decrease of 6.7 mm Hg with use of the timolol-dorzolamide fixed combination.

Initially, the interaction of latanoprost with miotic agents, such as pilocarpine, was not clear based on the early observation that pilocarpine antagonized PGF2a-induced ocular hypotension in monkeys (20).

This observation was not surprising because pilocarpine contracts the ciliary muscle, which can both decrease uveoscleral outflow and increase trabecular outflow facility by pulling on the scleral spur (see Chapter 32). In contrast, latanoprost lowers IOP by improving uveoscleral outflow, possibly through relaxation of the ciliary muscle, but primarily through remodeling the extracellular matrix (see “Mechanisms of Action”). This is consistent with an ultrasound biomicroscopy study of 36 healthy young Japanese persons showing that pilocarpine, 2%, increased the ciliary body thickness by 8.3% and latanoprost, 0.005%, decreased the thickness by 3.3% (104).

However, in clinical trials, it became apparent that pilocarpine did not impair the IOP-lowering effect of latanoprost (105), and it was demonstrated that these drugs were additive by fluorophotometric, pneumotonometric, and venomanometric methods (106). In a study of 20 patients with ocular hypertension who were initially treated with pilocarpine, 2%, three times daily or latanoprost, 0.005%, twice daily, the IOP reduction at the end of 1 week was 14.3% on pilocarpine alone and 23.4% on latanoprost alone (107). When pilocarpine was then added to the latanoprost, the additional IOP reduction was 7.4%, compared with 14.2% when latanoprost was added to pilocarpine. In patients who were on maximal medical therapy that included miotics, latanoprost had an additive effect, with additional IOP lowering (108, 109). Although the use of miotic therapies has declined with the availability of other drug classes with fewer ocular side effects and less frequent dosing, the miotic agents are expected to have an additive effect in combination with the prostaglandin-related drugs.

In general, there are few studies to support switching within the class of the prostaglandin agents. It has been suggested that unoprostone may have additive IOP lowering to latanoprost on the basis of a study of 41 patients (110). This additive effect was not supported in another study of 52 patients in which half the patients were initially treated with latanoprost for 6 weeks followed by adding unoprostone, and the other half of patients were treated initially with unoprostone and later adding latanoprost (111). The

combination of unoprostone with latanoprost did not result in further IOP lowering compared with latanoprost alone. It appears that unoprostone is not likely very useful as an adjunctive prostaglandin agent in patients who are already on another prostaglandin agent.

There is awareness that a small number of patients are nonresponders to latanoprost (112, 113), which would also be expected for the other prostaglandin-related agents. In 15 patients who were classified as nonresponders to latanoprost, which was defined as less than 10% IOP lowering after 6 to 8 weeks of latanoprost, 0.005%, administered once daily, bimatoprost (18.2 mm Hg on bimatoprost treatment) was more effective than latanoprost (24.1 mm Hg on latanoprost treatment) (114). The mechanism to explain the variation in IOP response to latanoprost versus bimatoprost in the same group of patients is not understood.

SIDE EFFECTS

Several side effects have been reported for the prostaglandin class of glaucoma medications that appear unique to this drug class compared with the other types of glaucoma medications. Most of these side effects are associated with use of latanoprost, because clinical experience has been longer with this agent than with unoprostone, bimatoprost, or travoprost. In general, these side effects are not common and a causal relationship has not been established. Although some of these side effects were not apparent in the well-designed glaucoma pharmacology clinical trial, it should be appreciated that new side effects or unanticipated effects are observed in the postmarketing use of a drug in individual patients who do not reflect the average participant in the clinical trials.

In general, based on the various clinical trials, the prostaglandin-related agents were associated with greater conjunctival hyperemia compared with timolol-treated eyes (39, 40 and 41, 60, 71). The hyperemia frequency rates in the product labeling are 5% to 15% for latanoprost, 0.005%; 15% to 45% for bimatoprost, 0.03%; 35% to 50% for travoprost, 0.004%; and 10% to 25% for unoprostone, 0.15%. The tremendous variation in the frequency of this side effect among the clinical trials depended on the particular dosing regimen used and the method used to ascertain this clinical finding, which may be elicited by patient report, by discontinuation rate for hyperemia, by grading based on clinical photographs, or by investigators' severity scoring (115). Several studies have compared the prostaglandin-related drugs to each other, and in general,

P.407

all the prostaglandin-related agents were associated with some degree of conjunctival hyperemia (57, 62, 75, 116).

Figure 28.3 Increased pigmentation of the iris in a patient taking prostaglandin therapy for glaucoma for 10 months. This side effect occurs primarily in patients with green-brown or blue-gray-brown iris color. (From Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology. 1996;103(1):126-137, with permission.)

The effect of latanoprost on conjunctival fibroblasts and conjunctiva has been examined. In rabbits treated with topical latanoprost, there was upregulation of matrix metalloproteinase type 3 compared

with control and timolol-treated eyes (117). Latanoprost increased the number of fibroblasts that stained for proliferating cell nuclear antigen, a marker for proliferating cells, compared with control treated rabbit eyes (118). With 6 months of latanoprost treatment in patients, the drug appeared to have transient effects on goblet cell density and was associated with a decrease in conjunctival epithelial cell size based on impression cytology staining comparing the status before and after treatment (119). A control patient population was not examined in that study. The effect of these agents on conjunctival biology and function is not fully understood regarding the impact of glaucoma drugs on the tissues and outcome of filtration surgery.

The main concern for corneal toxicity associated with prostaglandin treatment is an eye with a history of herpes simplex keratitis. There are case reports of reactivation of herpes simplex keratitis in patients treated with latanoprost or bimatoprost (120, 121). In a rabbit model, topical latanoprost increased the severity and recurrence or herpetic keratitis (122), and unoprostone did not (123). In a patient with a history of herpetic keratitis, an alternative drug class would be prudent for initial drug treatment for glaucoma. Superficial epithelial lesions of the cornea have been reported after latanoprost treatment (40, 124). In a 1-year clinical trial comparing latanoprost, fixed-combination latanoprost-timolol, and timolol, all three treatments had similar long-term corneal effects with little change in corneal endothelial cell density and corneal thickness (125).

The intraocular inflammatory effects of aqueous cell and flare and miosis, which result from the administration of large doses of prostaglandins, were not seen in animal or human eyes in the doses associated with the ocular hypotensive response (126, 127 and 128). The absorptive transport systems of the ciliary processes appear to prevent topically applied prostaglandins and other eicosanoids from causing retinal toxicity (129). Although, in general, this class of drug is well tolerated in a large number of patients, a few patients developed anterior uveitis while on latanoprost or cystoid macular edema after treatment with latanoprost (130, 131, 132, 133 and 134). Similarly, there are reported cases of cystoid macular edema associated with use of unoprostone, travoprost, and bimatoprost (135). Cautious use of this class of drugs is advised in eyes with risk factors for cystoid macular edema (135, 136).

The most visible side effect of the prostaglandin drug class is increased pigmentation in the periocular skin and iris and alterations in the eyelid cilia. Increased periocular skin pigmentation has been reported with the use of the prostaglandin agents (137). Instructing patients to wipe off any excess drops on the periocular skin area is important to minimize exposure of this area to this effect, which is reversible upon cessation of the drug exposure. Darkening of the iris was seen in 10% of the patients in one study (39), and also with the other prostaglandin agents (138). This was reported to occur more commonly in eyes with mixed green-brown or blue-graybrown iris color (Fig. 28.3) but has also been reported in a brown iris (39, 139). The mechanism appears to be similar in the iris and epidermal melanocytes with upregulation of tyrosinase activity in melanocytes (140, 141). In the pigmented rabbit model of lighter colored iris from sympathetic denervation, treatment of this eye with latanoprost darkened the iris in the denervated eye (142). Both light and electron microscopy studies indicate that the melanin content is increased in iris stromal melanocytes without proliferation of cells (143, 144 and 145). Because the alteration in iris color relates to iris stromal melanocytes, this is not expected to be related to open-angle glaucoma related to pigment dispersion (see Chapter 17), which in general is related to release of intraocular pigment by disruption of the pigmented epithelium on the posterior surface of the iris. Reports of prostaglandin-associated alterations in eyelid cilia include hypertrichosis and increased pigmentation (146).

P.408

Their effect on eyelash prominence is further highlighted by the recent U.S. Food and Drug Administration approval of bimatoprost, 0.03%, for treatment of hypotrichosis of eyelashes. For some patients, this side effect is beneficial and desirable, especially in the setting of chemotherapy-induced hair loss (147). The mechanism responsible for this side effect involves stimulating the growth phase of the hair cycle in the dermal papilla (148).

Other reactions reported to be associated with latanoprost include allergic contact dermatitis, iris cyst

associated with latanoprost, and herpes simplex dermatitis (149, 150 and 151).

With regard to systemic side effects, the amount of prostaglandin entering the circulation from the low doses of its ester that is required to lower the IOP is a small fraction of the amount of endogenous prostaglandins that are normally released from virtually all tissues of the body (129). No significant systemic reactions were reported with latanoprost in any of the clinical trials (39, 40, 152). In a crossover study comparing the effect of 6-day treatment with latanoprost and placebo, 24 patients with asthma had no alteration in respiratory function and asthmatic symptoms (153). Another study of 141 patients with newly diagnosed glaucoma included cardiovascular and respiratory examinations at baseline and after 3 months of treatment with betaxolol, brimonidine, latanoprost, or timolol (154). There were no statistically significant changes in the cardiovascular and spirometry measurements in the treated patients with the exception of timolol, which was associated with a decrease in peak flow. It appears that the prostaglandin agents have little clinical effect on cardiac and respiratory systems.

KEY POINTS

The prostaglandin agents are effective in lowering IOP and are practically used as first-line treatment agents.

At high levels, these ubiquitous local hormones produce ocular inflammation and ocular hypertension, but in smaller amounts, they reduce IOP. The prostaglandin agents are well tolerated and have virtually no systemic side effects.

The main mechanism of action for reducing IOP is primarily by improving uveoscleral outflow with a proposed biochemical effect of altering the extracellular matrix.

Caution should be used in considering alternative medical treatment to the prostaglandins if a patient has a history of uveitis or herpes simplex keratitis.

REFERENCES

1.Itoh S, Lu R, Bao Y, et al. Structural determinants of substrates for the prostaglandin transporter PGT. Mol Pharmacol. 1996;50(4): 738-742.

2.Ferreira S, Vane JR. Prostaglandins: their disappearance and release into the circulation. Nature. 1967;216:868-873.

3.Kurzrok R, Lieb CC. Biochemical studies of human semen: II. The action of semen on the human uterus. Proc Soc Exp Biol Med. 1930;28: 1056-1057.

4.Ambache N. Irin, a smooth-muscle contracting substance present in rabbit iris. J Physiol. 1955;129 (3):65-66.

5.Camras C, Bito LZ, Eakins KE. Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits. Invest Ophthalmol Vis Sci. 1977;16:1125-1134.

6.Giuffre G. The effects of prostaglandin F2 alpha in the human eye. Graefes Arch Clin Exp Ophthalmol. 1985;222(3):139-141.

7.Resul B, Stjernschantz J, Selen G, et al. Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids. Surv Ophthalmol. 1997;41(suppl 2):S47-S52.

8.Maxey KM, Johnson JL, LaBrecque J. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol. 2002;47(4 suppl 1):S34-S40.

9.Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev. 1994;46(2):205-229.

10.Pierce KL, Gil DW, Woodward DF, et al. Cloning of human prostanoid receptors. Trends Pharmacol Sci. 1995;16(8):253-256.

11.Pierce KL, Bailey TJ, Hoyer PB, et al. Cloning of a carboxyl-terminal isoform of the prostanoid FP receptor. J Biol Chem. 1997;272:883-887.

12.Bito LZ, Stjernschantz J, eds. The Ocular Effects of Prostaglandins and Other Eicosanoids. New York, NY: Alan R. Liss; 1989.

13.Matsuo T, Cynader MS. Localisation of prostaglandin F2 alpha and E2 binding sites in the human

eye. Br J Ophthalmol. 1992;76(4):210-213.

14.Anthony TL, Pierce KL, Stamer WD, et al. Prostaglandin F2 alpha receptors in the human trabecular meshwork. Invest Ophthalmol Vis Sci. 1998;39(2):315-321.

15.Kamphuis W, Schneemann A, van Beek LM, et al. Prostanoid receptor gene expression profile in human trabecular meshwork: a quantitative real-time PCR approach. Invest Ophthalmol Vis Sci. 2001;42(13):3209-3215.

16.Lee PY, Podos SM, Severin C. Effect of prostaglandin F2 alpha on aqueous humor dynamics of rabbit, cat, and monkey. Invest Ophthalmol Vis Sci. 1984;25(9):1087-1093.

17.Crawford K, Kaufman PL, Gabelt BT. Effects of topical PGF2 alpha on aqueous humor dynamics in cynomolgus monkeys. Curr Eye Res. 1987;6(8):1035-1044.

18.Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100(9):1297-1304.

19.Serle JB, Podos SM, Kitazawa Y, et al. A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes. Jpn J Ophthalmol. 1998;42(2):95-100.

20.Crawford K, Kaufman PL. Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of uveoscleral outflow by prostaglandin F2 alpha. Arch Ophthalmol. 1987;105(8):1112-1116.

21.Poyer JF, Millar C, Kaufman PL. Prostaglandin F2 alpha effects on isolated rhesus monkey ciliary muscle. Invest Ophthalmol Vis Sci. 1995;36(12):2461-2465.

22.Thieme H, Stumpff F, Ottlecz A, et al. Mechanisms of action of unoprostone on trabecular meshwork contractility. Invest Ophthalmol Vis Sci. 2001;42(13):3193-3201.

23.Crawford KS, Kaufman PL. Dose-related effects of prostaglandin F2 alpha isopropylester on intraocular pressure, refraction, and pupil diameter in monkeys. Invest Ophthalmol Vis Sci. 1991;32 (3):510-519.

24.Gabelt BT, Gottanka J, Lutjen-Drecoll E, et al. Aqueous humor dynamics and trabecular meshwork and anterior ciliary muscle morphologic changes with age in rhesus monkeys. Invest Ophthalmol Vis Sci. 2003;44(5):2118-2125.

25.Lindsey JD, To HD, Weinreb RN. Induction of c-fos by prostaglandin F2 alpha in human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1994;35(1):242-250.

26.Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol. 1997;9(2):240-246.

27.Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5(8):2145-2154.

28.Weinreb RN, Kashiwagi K, Kashiwagi F, et al. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1997;38(13):2772-2780.

29.Kashiwagi K, Jin M, Suzuki M, et al. Isopropyl unoprostone increases the activities of matrix metalloproteinases in cultured monkey ciliary muscle cells. J Glaucoma. 2001;10(4):271-276.

30.Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res. 1998;67(2):179-191.

P.409

31.Gaton DD, Sagara T, Lindsey JD, et al. Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2 alpha)-isopropyl ester treatment. Arch Ophthalmol. 2001;119(8):1165-1170.

32.Lindsey JD, Gaton DD, Sagara T, et al. Reduced TIGR/myocilin protein in the monkey ciliary muscle after topical prostaglandin F(2alpha) treatment. Invest Ophthalmol Vis Sci. 2001;42(8):17811786.

33.Weinreb RN, Lindsey JD. Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest Ophthalmol Vis Sci. 2002;43(3):716-722.

34.Sagara T, Gaton DD, Lindsey JD, et al. Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol. 1999;117(6):794-

35.Costa VP, Harris A, Stefansson E, et al. The effects of antiglaucoma and systemic medications on ocular blood flow. Prog Retin Eye Res. 2003;22(6):769-805.

36.Green K, Kim K. Interaction of adrenergic antagonists with prostaglandin E2 and tetrahydrocannabinol in the eye. Invest Ophthalmol. 1976;15(2):102-111.

37.Wang RF, Podos SM, Serle JB, et al. Effect of latanoprost or 8-iso prostaglandin E2 alone and in combination on intraocular pressure in glaucomatous monkey eyes. Arch Ophthalmol. 2000;118(1): 74-

38.Dijkstra BG, Schneemann A, Hoyng PF. Flow after prostaglandin E1 is mediated by receptorcoupled adenylyl cyclase in human anterior segments. Invest Ophthalmol Vis Sci. 1999;40(11):26222626.

39.Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995;102(12):1743-1752.

40.Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology. 1996;103(1):126-137.

41.Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology. 1996;103(1):138-147.

42.Racz P, Ruzsonyi MR, Nagy ZT, et al. Around-the-clock intraocular pressure reduction with oncedaily application of latanoprost by itself or in combination with timolol. Arch Ophthalmol. 1996;114 (3):268-273.

43.Hedman K, Watson PG, Alm A. The effect of latanoprost on intraocular pressure during 2 years of treatment. Surv Ophthalmol. 2002;47(suppl 1):S65-S76.

44.Coppens G, Stalmans I, Zeyen T, et al. The safety and efficacy of glaucoma medication in the pediatric population. J Pediatr Ophthalmol Strabismus. 2009;46(1):12-18.

45.Enyedi LB, Freedman SF. Latanoprost for the treatment of pediatric glaucoma. Surv Ophthalmol. 2002;47(suppl 1):S129-S132.

46.Cheng JW, Cai JP, Li Y, et al. A meta-analysis of topical prostaglandin analogs in the treatment of chronic angle-closure glaucoma. J Glaucoma. 2009;18(9):652-657.

47.Aung T, Chan YH, Chew PT. Degree of angle closure and the intraocular pressure-lowering effect of latanoprost in subjects with chronic angleclosure glaucoma. Ophthalmology. 2005;112(2):267-271.

48.Kook MS, Cho HS, Yang SJ, et al. Efficacy of latanoprost in patients with chronic angle-closure glaucoma and no visible ciliary-body face: a preliminary study. J Ocul Pharmacol Ther. 2005;21(1):75-

49.Sakai H, Shinjyo S, Nakamura Y, et al. Comparison of latanoprost monotherapy and combined therapy of 0.5% timolol and 1% dorzolamide in chronic primary angle-closure glaucoma (CACG) in Japanese patients. J Ocul Pharmacol Ther. 2005;21(6):483-489.

50.Chew PT, Hung PT, Aung T. Efficacy of latanoprost in reducing intraocular pressure in patients with primary angle-closure glaucoma. Surv Ophthalmol. 2002;47(suppl 1):S125-S128.

51.Yamamoto T, Kitazawa Y, Azuma I, et al. Clinical evaluation of UF-021 (Rescula; isopropyl unoprostone). Surv Ophthalmol. 1997;41(suppl 2):S99-S103.

52.Azuma I, Masuda K, Kitazawa Y, et al. Double-masked comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glaucoma or ocular hypertension. Jpn J Ophthalmol. 1993;37(4):514-525.

53.Takase M, Murao M, Koyano S, et al. Ocular effects of topical instillation of UF-021 ophthalmic solution in healthy volunteers [in Japanese]. Nippon Ganka Gakkai Zasshi. 1992;96(10):1261-1267.

54.Nordmann JP, Mertz B, Yannoulis NC, et al. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including exfoliation glaucoma or ocular hypertension. 6 month data. Am J Ophthalmol. 2002;133(1):1-10.

55.Stewart WC, Stewart JA, Kapik BM. The effects of unoprostone isopropyl 0.12% and timolol maleate 0.5% on diurnal intraocular pressure. J Glaucoma. 1998;7(6):388-394.

56.Susanna RJ, Giampani JJ, Borges AS, et al. A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension. Ophthalmology. 2001;108(2):259-263.

57.Kobayashi H, Kobayashi K, Okinami S. A comparison of intraocular pressure-lowering effect of prostaglandin F2-alpha analogues, latanoprost, and unoprostone isopropyl. J Glaucoma. 2001;10(6):487-

58.Ooi YH, Oh DJ, Rhee DJ. Effect of bimatoprost, latanoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human ciliary body smooth muscle cells. Invest Ophthalmol Vis Sci. 2009;50(11):5259-5265.

59.Hellberg MR, McLaughlin MA, Sharif NA, et al. Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL6598, a DP prostaglandin receptor agonist. Surv Ophthalmol. 2002;47(suppl 1):S13-S33.

60.Goldberg I, Cunha-Vaz J, Jakobsen JE, et al. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2001;10(5):414-422.

61.Fellman RL, Sullivan EK, Ratliff M, et al. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Ophthalmology. 2002;109(5):998-1008.

62.Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132(4):472-484.

63.Orengo-Nania S, Landry T, Von Tress M, et al. Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. Am J Ophthalmol. 2001;132 (6):860-868.

64.Chen MJ, Chen YC, Chou CK, et al. Comparison of the effects of latanoprost and travoprost on intraocular pressure in chronic angleclosure glaucoma. J Ocul Pharmacol Ther. 2006;22(6):449-454.

65.Netland PA, Robertson SM, Sullivan EK, et al. Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension. Adv Ther. 2003;20(3):149-163.

66.Birt CM, Buys YM, Ahmed II, et al. Prostaglandin efficacy and safety study undertaken by race (The PRESSURE Study). J Glaucoma 2009;Dec 30 [Epub ahead of print]

67.Mansberger SL, Hughes BA, Gordon MO, et al. Comparison of initial intraocular pressure response with topical beta-adrenergic antagonists and prostaglandin analogues in African American and white individuals in the Ocular Hypertension Treatment Study. Arch Ophthalmol. 2007;125(4):454-459.

68.Porter AC, Felder CC. The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol Ther. 2001;90(1): 45-60.

69.Yu M, Ives D, Ramesha CS. Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem. 1997;272(34): 21181-21186.

70.Woodward DF, Liang Y, Krauss AH. Prostamides (prostaglandinethanolamides) and their pharmacology. Br J Pharmacol. 2008;153(3): 410-419.

71.Brandt JD, VanDenburgh AM, Chen K, et al. Comparison of onceor twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology. 2001;108(6): 1023-1031.

72.Higginbotham EJ, Schuman JS, Goldberg I, et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002;120(10):12861293.

73.Laibovitz RA, VanDenburgh AM, Felix C, et al. Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management. Arch Ophthalmol. 2001;119(7):994-1000.

74.DuBiner H, Cooke D, Dirks M, et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol. 2001;45(suppl 4):S353-

S360.

75.Gandolfi S, Simmons ST, Sturm R, et al. Bimatoprost Study Group. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001;18 (3):110-121.

P.410

76.Noecker RS, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135(1):55-63.

77.Bournias TE, Lee D, Gross R, et al. Ocular hypotensive efficacy of bimatoprost when used as a replacement for latanoprost in the treatment of glaucoma and ocular hypertension. J Ocul Pharmacol Ther. 2003; 19(3):193-203.

78.Bhorade AM, Gordon MO, Wilson B, et al. Variability of intraocular pressure measurements in observation participants in the Ocular Hypertension Treatment Study. Ophthalmology. 2009;116(4):717-

79.How AC, Kumar RS, Chen YM, et al. A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma. Br J Ophthalmol. 2009;93(6):782-786.

80.Chen MJ, Chen YC, Chou CK, et al. Comparison of the effects of latanoprost and bimatoprost on intraocular pressure in chronic angleclosure glaucoma. J Ocul Pharmacol Ther. 2007;23(6):559-566.

81.Wan Z, Woodward DF, Cornell CL, et al. Bimatoprost, prostamide activity, and conventional drainage. Invest Ophthalmol Vis Sci. 2007; 48(9):4107-4115.

82.Brubaker RF, Schoff EO, Nau CB, et al. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol. 2001;131(1):19-24.

83.Nagasubramanian S, Sheth GP, Hitchings RA, et al. Intraocular pressurereducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens. Ophthalmology. 1993;100(9):1305-1311.

84.Stjernschantz J, Selen G, Sjoquist B, et al. Preclinical pharmacology of latanoprost, a phenylsubstituted PGF2 alpha analogue. Adv Prostaglandin Thromboxane Leukot Res. 1995;23:513-518.

85.Woodward DF, Krauss AH, Chen J, et al. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol. 2001;45(suppl 4):S337-S345.

86.Sjoquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002;47(suppl 1):S6-S12.

87.Morgan PV, Proniuk S, Blanchard J, et al. Effect of temperature and light on the stability of latanoprost and its clinical relevance. J Glaucoma. 2001;10(5):401-405.

88.Villumsen J, Alm A. The effect of adding prostaglandin F2 alphaisopropylester to timolol in patients with open angle glaucoma. Arch Ophthalmol. 1990;108(8):1102-1105.

89.Higginbotham EJ, Diestelhorst M, Pfeiffer N, et al. The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications. Surv Ophthalmol. 2002;47(suppl 1):S133-S140.

90.Polo V, Larrosa JM, Ferreras A, et al. Effect on diurnal intraocular pressure of the fixed combination of latanoprost 0.005% and timolol 0.5% administered in the evening in glaucoma. Ann Ophthalmol (Skokie). 2008;40(3-4):157-162.

91.Centofanti M, Oddone F, Vetrugno M, et al. Efficacy of the fixed combinations of bimatoprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multicenter, randomized, investigator-masked, clinical study. Eur J Ophthalmol. 2009;19(1): 66-71.

92.Calissendorff B, Sjoquist B, Hogberg G, et al. Bioavailability in the human eye of a fixed combination of latanoprost and timolol compared to monotherapy. J Ocul Pharmacol Ther. 2002;18 (2):127-131.

93.Rossi GC, Pasinetti GM, Bracchino M, et al. Switching from concomitant latanoprost 0.005% and timolol 0.5% to a fixed combination of travoprost 0.004%/timolol 0.5% in patients with primary openangle glaucoma and ocular hypertension: a 6-month, multicenter, cohort study. Expert Opin Pharmacother. 2009;10(11):1705-1711.